median
Navigation Links
median at medicine technology
Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
...dings are as follows: * There was no advantage in median time to tumour progression inthe ASA404 arm compar...of patients in both arms were alive after oneyear, median survival values have not been determined *Independently-determined response rates were consistent wi......ed,Collins and coauthors were able to estimate the median number ofhours per week spent below the 1 IU/dL trough level for eachpopulation, 19.7 hours and 16.5 hours for the one to six year oldand 10 to 65 years old groups respectively. Subsequent comparisonwith bleed frequency for each group found that in t...Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
...30. Forthe 38 evaluable patients in the trial, the median time to PSAprogression has not been reached and is currently estimated to be252 days (8.4 months). Abiraterone, an oral, irreversible CYP450c17 enzyme inhibitorappears to have activity in post-docetaxel castration resistantprostate cancer The Phase......tically significant difference (p=0.028) -- The median change in CD4 cell count from baseline was similar between the PREZISTA/r and lopinavir/r arms (88 cells per cubic millimeter vs. 81 cells per cubic millimeter) Development of resistance also was studied. Findings include: -- 10 pe...Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients
...ated patients who did not develop arash survived a median of 3.3 months, compared to 7.1 months forthose wit... inthese patients was also significantly longer (a median of 8.2months compared to 4.7 months), compared to placebo patients whodidn’t develop a rash. &...Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
...atient met the criteria for a PSA response and the median timeto PSA or clinical progression was 9 weeks. I...reviewed,ranged from 7.1 weeks to 30.0 weeks. The median time toprogression in the treated population was 5.9 weeks. Theadverse events were manageable, pred......(lenalidomide) plus thesteroid dexamethasone shows median survival of 35 months, nearlythree years. The data...experts here are saying that nearly three years of median over allsurvival for REVLIMID patients is the longest they have seen inmyeloma to-date from large cl......teroid dexamethasone showed an unprecedented median survival of nearly three years (35 months) for ...uropesince 2004. VELCADE as a single agent shows a median overallsurvival in this patient population of two and a half years (29.8months) with "robust respons......untreated MM patients aged 65 years or olderwith a median age of 75 years. The study included 54 evaluablepatients ineligible for SCT. Patients received VELCADE at 1.0mg/m(2) or 1.3 mg/m(2) on days 1, 4, 8, 11, 22, 25, 29 and 32 forfour six-week cycles, then on days 1, 8, 15 and 22 for fivefive-week cycles.......d/progressive myeloma (patients to date have had a median of7 prior therapies). As reported, of the 14 patients treated 5consecutive days, there are 10 patients evaluable for efficacy,with 4 out of the 10 (40%) achieving stable disease greater than 4months duration. Data from the twice weekly study is not y...CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
...-----------------------------(a) Data provided are median change from baseline to day 42. For CRx-150 treated subjects, median baseline pain as measuredon a visual analogue scale (VAS), went from 63.0mm to 37.0mm at day42, with...... after injection), lengthof pain relief, lasting a median of four months in respondingpatients, and predictable and reversible bone marrow toxicity ormyelosuppression that tends to return to pretreatment levels aftereight weeks. QUADRAMET is administered as a single intravenousinjection, usually on an outpa...Gentium's Defibrotide Seen as Active in Multiple Myeloma
... other thromboprophylaxis wasadministered. After a median of 3 cycles, the major response rate,including complete and partial remission was 53% (1CR, 1nCR and7PR). Responses were seen in all three Defibrotide dose levels.Follow up remains limited and the durability of response appearsfavorable. MTD was not ......he 17 still on treatmentfor up to nine cycles. The median survival time and median time toprogression have not been reached, with estimated actuarialsurvival of 69% at 12 months. Pati......ompensated liver disease treated with Hepsera fora median of 49 weeks up to a maximum of 240 weeks. Changes ...retreated with Hepsera for up to 129 weeks, with a median time ontreatment of 19 and 56 weeks, respectively. Clinical and laboratoryevidence of exacerbations ......ompensated liver disease treated with Hepsera fora median of 49 weeks up to a maximum of 240 weeks. Changes ...retreated with Hepsera for up to 129 weeks, with a median time ontreatment of 19 and 56 weeks, respectively. Clinical and laboratoryevidence of exacerbations ......iously been treated an average of 5.2+/-1.8 (1, 8; median 5.4)years earlier at Baylor College of Medicine under the direction ofJingwu Zhang, M.D., Ph.D with a T-cell vaccine developed frommyelin basic protein (MBP) reactive T-cells. The safety profilerevealed only injection site mild reactions and no sever...Eurand's Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
...ollowing Zentase treatment with a 43 percent median increase in CFA. -- Consistently Improved EPI Symptoms. Zentase treatment improved the signs and symptoms of malabsorption even in patients with CFA values greater than 80 percent under placebo. -- Well Tolerated. There were no u......tudy. At the time of reporting, 58 patients with a median of 3prior therapies have completed treatment. Patients were treatedonce weekly for two or three consecutive weeks and the (90)Y dosewas escalated in successive patient cohorts. For patients withprior bone marrow transplants, dose escalation stopped a...Studies Show Efficacy and Safety of Alexion's Soliris in Broad Population of PNH Patients
...ng from one tomore than 10 years.(8) The estimated median survival for PNHpatients is between 10 and 15 years from the time ofdiagnosis.(6)(8) PNH has been identified more commonly among patients withdisorders of the bone marrow, including aplastic anemia (AA) andmyelodysplastic syndrome (MDS).(9)(10)(11)(......ompensated liver disease treated with Hepsera fora median of 49 weeks up to a maximum of 240 weeks. Changes ...retreated with Hepsera for up to 129 weeks, with a median time ontreatment of 19 and 56 weeks, respectively. Clinical and laboratoryevidence of exacerbations ...Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia
...e condition occurs primarily in older people witha median age at diagnosis of 66 years. Men are twice as likely aswomen to develop the disease. The clinical course of the conditionvaries widely with some patients showing rapid disease progressionand early death, despite intensive chemotherapy, and otherssur......etthe primary endpoint of significantly increasing median duration ofprogression-free survival in patients w...notecan achieved anoverall response rate of 27%, a median progression-free survivalduration of more than 4 months, and an overall median survival of9.7 months...IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial
...gression free survival (PFS) was 4.8 months with a median follow-up of 12 months. -- Overall survival (OS) has not yet been reached as 21 patients are still alive. The survival rate at 9 months was 70%. -- Immune response: 26 out of 29 evaluated patients (90%) showed detectable......rticularly aggressive form oflymphoma with a short median duration of life expectancy(approximately two years) from diagnosis. About Romidepsin Romidepsin is a novel agent in a new class of anti-cancer drugsknown as histone deacetylase inhibitors. The Company is conductinga pivotal phase II study of romid......the Dacogen treated patients was 12.6 months, the median duration of response was 8.8 months, and1- and 2-y...n), consisting of two cycles of each agent. Aftera median follow-up of 132 weeks, the group that received Gliadel had an extendedmedian survival of 89.4 week...Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
...e, 19 elected tosubsequently receive STA-4783. The median overall survival for thisgroup was 14.3 months. By...did not subsequently receiveSTA-4783 experienced a median survival of 5.6 months. Otherrandomized trial results in metastatic melanoma have consistentlyshown ...Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
...ients' stable disease was fourto 12 months, with a median of six months. These data show that the combinati...yranging from two to nine prior therapies with the median beingfour. In addition, 59 percent of enrolled patients had priorradiation treatment and 86 percent ...Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
...loped into a complete response - Current median duration of stable disease (from five of the six studies) was more than 15.4 weeks (median duration of objective response has not yet been reached). Twenty-five patients continue to respond with the longest response still ongoing at f......lyNSCLC(1). The final analysis was performed at a median follow-up of 28months. At this time, 41 of the 122 patients receiving MAGE-A3relapsed (30.6%); in comparison to 26 of the 60 patients receivingplacebo (43.3%). Using a Cox regression model to adjust for thefact that patients in the different arms wer......n), consisting of two cycles of each agent. Aftera median follow-up of 132 weeks, the group that received Gliadelhad an extended median survival of 89.4 weeks (95% CI, 65.1-(Infinity)) compared to 72.7 weeks (95% CI, 57.7-84.3) for pati......f therapy.Patients in the CAELYX arm experienced a median improvement in timeto progression of three months ...onths; p=0.0005). The patients in the study had a median age of 57, and had adequatebone marrow, renal, hepatic and cardiac function. These patientshad exper......eIII disease. In the study, participants reached a median 88 percent and 83percent relative dose intensity, ...se data represent the plannedfinal analysis with a median follow-up of 3.8 years; studyparticipants will be followed for survival for a total of 10years. ......ients treated with the Taxotere(R) regimen lived a median ofthree months longer (19.3 months versus 16.3 mon...advantage, versusmitoxantrone plus prednisone. The median survival was 18.9 monthsin the group given docetaxel every 3 weeks and 16.5 months in themitoxantron...... The results showed patients on XYOTAX had longer median survival(220 days vs. 198 days; p=0.686) with significantly fewer adverseevents (all grades; 2.0 vs. 3.0; p=0.011), despite receiving morechemotherapy cycles (3.9 vs. 3.4; p=0.007). In addition, XYOTAXpatients had fewer outpatient visits (0.6 vs. 1.7......valuesat entry were in the low normal range with a median value of 3.7mIU/mL. After three months of treatment LH increased to normalvalues of 5.8 and 8.1 in the Androxal 12.5mg and 25mg groups,respectively, remained unchanged at 3.3 in the placebo group butdecreased significantly to 0.3 in the Androgel grou....... For patients who achievedcomplete remission, the median time before their disease progressedwas 9.2 years....m, clinical trial in 40 patients who hadreceived a median of four prior chemotherapies and whose diseasehad not responded to or had progressed after at least ......potecan patients showed aresponse to the drug. The median duration of progression freesurvival at the interim analysis was 4.1 months for Amrubicinpatients compared to 2.0 months for topotecan patients. Patientsare being followed for overall survival. Thirty patients in the trial were evaluable for toxicit......-Dieu. "Based on the Phase II trial, whichshowed a median overall survival greater than 38 months, we believethat the strong efficacy of the combination in the Phase III trialwill extend to a substantial improvement in overall survival aswell." The Phase III study compared the efficacy and safety of thecom...... doses were also better than placebo with regardto median time of progression-free survival: 794 days (95%confidence interval: 155.0, not estimable) for the lower ONTAKdose, greater than 971 days (median not reached) for the higherONTAK dose, and 124 days (95% confidence interval: 92.0, 176.0) forplacebo. ....... There was a statistically significantincrease in median survival for each of the responder populationscompared to the 6 month median survival of the non-responders (pless than 0.0016). "The 41 month median duration of survival for......streated with the GaRD regimen, 46% are alive at a median followup of 17+ months, and 7are currently without evidence of disease. No non-hematologic Grade 4 adverse events were reported. Grade 4lymphopenia, neutropenia and thrombocytopenia were observed in 1, 2 and 2 patients,respectively. Grade 1-3 anemia......ve and progression free at six months, and showeda median progression free survival (PFS) of 8.1 months. In ...se IIItrial [overall population: 54% 6 months PFS, median PFS of 6.9months;(1) methylated MGMT gene promoter subgroup: 69% PFS and 10.3months median PFS].(2) ......=45). Theobjective response rate was 66% and, at a median follow-up of 14.9months, the median time to progression was 8.7 months and theoverall survival was 16.8 months Neurotoxicity and alopeci......was 0.52 (95% CI: 0.42-0.65,p=0.000000002), with a median time to progression of 15.3 weeks forthe satraplatin arm compared to 5.6 weeks for control. These dataare consistent with the PFS outcomes as adjudicated by the blindedindependent review committee. Safety findings in the SPARC trial were consistent ......tumor and adjuvant radiation andchemotherapy. The median overall survival for these patients was previously...ult which compares favorably tothe 17 to 22 months median survival results published from multiplestudies in patients undergoing pancreatic cancer surgery and...Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
...ciety of ClinicalOncology (ASCO) showed that, with median follow-up of nearly threeyears, the addition of He... in theproduct label, data that showed an improved median overall survivalfor women with HER2-positive metastatic breast cancer treatedinitially with Hercepti......gatorof the trial. "In a patient population with a median age of nearly80 years old, a survival advantage of this magnitude is remarkable.MP-T therapy should become the reference treatment for all elderlypatients with newly diagnosed multiple myeloma." Pharmion has submitted an application with the Europea...Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
...ng from one to more than 10 years.(7) Theestimated median survival for PNH patients is between 10 and 15years from the time of diagnosis.(5)(11) About Soliris Soliris is the first therapy approved by the U.S. Food and DrugAdministration for the treatment of PNH. Soliris is indicated forthe treatment of pa......ession of the disease compared to IROXand IFL. The median TTP was significantly longer amongFOLFOX4-treated patients at 9.2 months compared to 6.5 months withIROX (p=<.001) and 6 months with IFL (p=<.001). FOLFOX4patients were significantly more likely to experience any grade 3or greater side effect...... of Clinical Oncology (ASCO) in Chicago, IL. At a median follow-up of three years, FOLFOX4 treatment givenb...e of the trial was todemonstrate a 40% increase in median PFS, with 80% power andtwo-sided significance level of 5%, resulting in HR=0.71. Safetydata, a secon......ived both hyperthermiatherapy and chemotherapy the median disease free survival was 31.7months, compared to ...d chemotherapyalone (p=0.004), a 95% increase. The median local progression freesurvival rate was estimated at 45.3 months for patients whoreceived chemothera......was 0.52 (95% CI: 0.42-0.65,p=0.000000002), with a median time to progression of 15.3 weeks forthe satraplatin arm compared to 5.6 weeks for control. These dataare consistent with the PFS outcomes as adjudicated by the blindedindependent review committee. Safety findings in the SPARC trial were consistent ...... (12 month survival). Regarding Overall Survival, median survival was 19.3 months forpatients in the TNFerade + SOC arm versus 11.1 months for patientsreceiving standard of care alone. Tumor Response was defined asComplete Response + Partial Response + Stable Disease at week 12post-treatment, and there was...New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting
...wing forre-treatment after cycle one. At baseline, median Gleason Score waseight, median PSA values were 162 ng/ml and 43% of patients hadpreviously received taxane-based chemotherapy. Foll......ients had ovariancancer (HER2 status unknown). The median number of prior regimensexcluding hormonal therapy was 6.5, and the median priortrastuzumab-containing regimens for the HER2-positive breast cancerpatients was 4. Clinical ben...Cardiome And Astellas Announce Positive Results From ACT 2 Trial
...erted tonormal heart rhythm within 90 minutes, the median time toconversion was 12 minutes from the initiation of dosing. "We are delighted to see a 47% conversion rate in post-operativeatrial fibrillation patients, and in particular we are encouragedby the safety profile observed in this fragile patient p......s treated with the GaRD regimen, 46%are alive at a median followup of 17+ months, and 7 are currentlywithout evidence of disease. No non-hematologic Grade 4 adverse events were reported. Grade 4lymphopenia, neutropenia and thrombocytopenia were observed in 1, 2and 2 patients, respectively. Grade 1-3 anem......cy The primary endpoints of the study were either median fastingplasma triglyceride (TG) levels after admin...e diet.For all subjects a substantial reduction of median TG levels wasobserved. Three patients (one from the low dose and 2 from the middose group) hit the p...Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research
...lts of the MOSAIC trial,including survival, with a median follow-up of 6 years. -- A long-term update including disease-free-survival and overall survival data from the MOSAIC study, which evaluates the role of oxaliplatin/5FU/LV (FOLFOX4) as adjuvant treatment for stage II and III co...Other ContentsaspirinaspirinaspirinaspirinchildrenchildrenchildrenchildrenchildrenchildrenchildrenchildrenchildrenastigmatismastigmatismasymptomaticasymptomaticasymptomaticasymptomaticataxiaataxiaataxiaatelectasisOther TagsLesbianKenyanMyanmarPreeclampsia
(Date:8/20/2008)...ng (MRI) isn,t just for capturing detailed images ...gents and technology developed by Carnegie Mellon ...to visualize with "exquisite" specificity cell p...lity to non-invasively locate and track cells, suc...treatment of cancer, inflammation, and autoimmune ...
(Date:8/20/2008)...nd with Additional Funding by Syncom Venture Part...luding Lockheed Martin, GE Security, Baker Capi...wswire/ -- Clear(R), the fast pass for airport,sec...g. Led by new investor,Spark Capital, this round a...ners, and existing investors Lockheed Martin, GE S...
(Date:8/20/2008)...codeine may be risky for some,breastfeeding mothe...Western Ontario, and the Hospital for Sick Childre...oren published research in the journal, Clinical ...he codeine used in some pain relief drugs can actu...ts when ingested by some breastfeeding mothers. ,...
(Date:8/20/2008)...at an interdisciplinary and coordinated research a...nce and influencing policy, a group of experts has...ng of how mercury moves through the marine ecosyst...uth,s Toxic Metals Research Program convened the g...ators, and public health experts in November 2006 ...
Breaking Biology News(10 mins):Carnegie Mellon MRI technology that non-invasively locates, quantifies specific cells in the body 2Carnegie Mellon MRI technology that non-invasively locates, quantifies specific cells in the body 3Clear(R) Secures $44.4 Million in Venture Funding 2Clear(R) Secures $44.4 Million in Venture Funding 3Codeine not safe for all breastfeeding moms and their babies 2Dartmouth workshop sets research agenda for environmental mercury 2NCD 30 Years of Disability Policy Leadership 1978 2008 18787 1NCD 30 Years of Disability Policy Leadership 1978 2008 18787 2NCD 30 Years of Disability Policy Leadership 1978 2008 18787 3NCD 30 Years of Disability Policy Leadership 1978 2008 18787 4Alpharma Presents Data Addressing Abuse Liability Features Safety and Efficacy on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release wi 2014 1Alpharma Presents Data Addressing Abuse Liability Features Safety and Efficacy on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release wi 2014 2Alpharma Presents Data Addressing Abuse Liability Features Safety and Efficacy on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release wi 2014 3Alpharma Presents Data Addressing Abuse Liability Features Safety and Efficacy on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release wi 2014 4Alpharma Presents Data Addressing Abuse Liability Features Safety and Efficacy on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release wi 2014 5Alpharma Presents Data Addressing Abuse Liability Features Safety and Efficacy on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release wi 2014 6Alpharma Presents Data Addressing Abuse Liability Features Safety and Efficacy on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release wi 2014 7Do antidepressants enhance immune function 3F 18782 1Do antidepressants enhance immune function 3F 18782 2Hill Rom to Present at the Citi Healthcare Conference 18778 1(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2[0] Cytiva's one45 Software Rebrands Healthcare Education Administration Products[0] Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events[0] New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation[0] Women's Alcohol Use Tied to Delayed Childbearing
MilkingLesbianSandbagFluticasoneSubliminalForearmKenyanMyanmarPreeclampsiaBicycleAngelinaSwearingPolyunsaturatedDiclofenac
Other Tagsrhythms 2rhythms 3malignant 2malignant 3malignant 4malignant 5malignant 6malignant 7malignant 8malignant 9malignant 10restrict 2restrict 3restrict 4restrict 5restrict 6restrict 7properties 2properties 3properties 4properties 5properties 6properties 7properties 8properties 9properties 10| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |